MAP2K1 and colorectal carcinoma: Besides IGF-1R monotherapy, the combination of IGF-1R inhibitors with MEK1/2 inhibitors efficiently decreased the cell viability and increased apoptosis of CRC cells, overcoming the resistance to IGF-1R monotherapy [29].